The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study.

Karsdal MA, Byrjalsen I, Henriksen K, Riis BJ, Lau EM, Arnold M, Christiansen C

Osteoarthritis and cartilage1 Sept 2009Cited by 83 (Europe PMC)

PMID19747581DOI10.1016/j.joca.2009.08.004PepBankPUB-19747581

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialPharmacokinetics
In osteoarthritis patients, oral calcitonin 0.8 mg produced significantly higher C(max) than 0.6 mg, P=0.03.
In plain wordsIn osteoarthritis patients, oral calcitonin 0.8 mg produced higher peak concentrations than 0.6 mg.
Peptide
Calcitonin-salmon
Outcome
IncreaseCalcitonin C(max)
Study
n: not reported in source
Comparator
0.6 mg twice daily
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
0.8 mg twice daily · oral · 14 daysAs given in this study (human).
Measurements
P
0.03
0.8 mg versus 0.6 mg
Source sentences
Summary
Doses of 0.8 mg compared with 0.6 mg produced significantly higher C(max) and AUC(0-4 hrs), of calcitonin, P=0.03.
2 context sentences(design, population, supporting numbers)
Summary · context
The study was a phase-I, 2-week, placebo-controlled, double-blind, double-dummy, randomized, gender-stratified study including 73 subjects aged 57-75 years.
Summary · context
Treatment allocations were; 0.6 mg, 0.8 mg of oSCT, or placebo. Treatment was given twice daily for 14 days.
Report a problemFND-1974758101
02HumanRandomized controlled trialPharmacokinetics
In osteoarthritis patients, oral calcitonin 0.8 mg produced significantly higher AUC(0-4 hrs) than 0.6 mg, P=0.03.
In plain wordsIn osteoarthritis patients, oral calcitonin 0.8 mg produced higher exposure than 0.6 mg.
Peptide
Calcitonin-salmon
Outcome
IncreaseCalcitonin AUC(0-4 hrs)
Study
n: not reported in source
Comparator
0.6 mg twice daily
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
0.8 mg twice daily · oral · 14 daysAs given in this study (human).
Measurements
P
0.03
0.8 mg versus 0.6 mg
Source sentences
Summary
Doses of 0.8 mg compared with 0.6 mg produced significantly higher C(max) and AUC(0-4 hrs), of calcitonin, P=0.03.
2 context sentences(design, population, supporting numbers)
Summary · context
The study was a phase-I, 2-week, placebo-controlled, double-blind, double-dummy, randomized, gender-stratified study including 73 subjects aged 57-75 years.
Summary · context
Treatment allocations were; 0.6 mg, 0.8 mg of oSCT, or placebo. Treatment was given twice daily for 14 days.
Report a problemFND-1974758102
03HumanRandomized controlled trialEfficacy outcome
In osteoarthritis patients, oral calcitonin significantly reduced CTX-I, P<0.0001.
In plain wordsIn osteoarthritis patients, oral calcitonin significantly reduced CTX-I.
Peptide
Calcitonin-salmon
Outcome
DecreaseCTX-I reduction
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · oral · 14 daysAs given in this study (human).
Measurements
P
< 0.0001
CTX-I
Source sentences
Summary
This resulted in significant reductions in CTX-I and CTX-II, [P<0.0001; P=0.007].
3 context sentences(design, population, supporting numbers)
Summary · context
Doses of 0.8 mg compared with 0.6 mg produced significantly higher C(max) and AUC(0-4 hrs), of calcitonin, P=0.03.
Summary · context
The study was a phase-I, 2-week, placebo-controlled, double-blind, double-dummy, randomized, gender-stratified study including 73 subjects aged 57-75 years.
Summary · context
Treatment allocations were; 0.6 mg, 0.8 mg of oSCT, or placebo. Treatment was given twice daily for 14 days.
Report a problemFND-1974758103
04HumanRandomized controlled trialEfficacy outcome
In osteoarthritis patients, oral calcitonin significantly reduced CTX-II, P=0.007.
In plain wordsIn osteoarthritis patients, oral calcitonin significantly reduced CTX-II.
Peptide
Calcitonin-salmon
Outcome
DecreaseCTX-II reduction
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · oral · 14 daysAs given in this study (human).
Measurements
P
0.007
CTX-II
Source sentences
Summary
This resulted in significant reductions in CTX-I and CTX-II, [P<0.0001; P=0.007].
3 context sentences(design, population, supporting numbers)
Summary · context
Doses of 0.8 mg compared with 0.6 mg produced significantly higher C(max) and AUC(0-4 hrs), of calcitonin, P=0.03.
Summary · context
The study was a phase-I, 2-week, placebo-controlled, double-blind, double-dummy, randomized, gender-stratified study including 73 subjects aged 57-75 years.
Summary · context
Treatment allocations were; 0.6 mg, 0.8 mg of oSCT, or placebo. Treatment was given twice daily for 14 days.
Report a problemFND-1974758104
05HumanRandomized controlled trialOther
In osteoarthritis patients receiving oral calcitonin, gender had no observable influence on results.
In plain wordsIn osteoarthritis patients receiving oral calcitonin, gender had no observable influence on results.
Peptide
Calcitonin-salmon
Outcome
No significant changeInfluence of gender on results
Study
n: not reported in source
Comparator
Other gender
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · oral · 14 daysAs given in this study (human).
Source sentences
Summary
Gender had no observable influence on results.
2 context sentences(design, population, supporting numbers)
Summary · context
The study was a phase-I, 2-week, placebo-controlled, double-blind, double-dummy, randomized, gender-stratified study including 73 subjects aged 57-75 years.
Summary · context
Treatment allocations were; 0.6 mg, 0.8 mg of oSCT, or placebo. Treatment was given twice daily for 14 days.
Report a problemFND-1974758107
06HumanNon-randomized trialPharmacokinetics
In osteoarthritis patients, calcitonin pharmacokinetic parameters did not differ between baseline and day 14.
In plain wordsIn osteoarthritis patients, calcitonin pharmacokinetic parameters did not differ between baseline and day 14.
Peptide
Calcitonin-salmon
Outcome
No significant changePharmacokinetic parameters over time
Study
n: not reported in source
Comparator
Baseline
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated · oral · 14 daysAs given in this study (human).
Source sentences
Summary
No differences were observed between baseline and follow-up at day 14 in pharmacokinetic and pharmacodynamic parameters.
2 context sentences(design, population, supporting numbers)
Summary · context
The study was a phase-I, 2-week, placebo-controlled, double-blind, double-dummy, randomized, gender-stratified study including 73 subjects aged 57-75 years.
Summary · context
Treatment allocations were; 0.6 mg, 0.8 mg of oSCT, or placebo. Treatment was given twice daily for 14 days.
Report a problemFND-1974758105
07HumanNon-randomized trialEfficacy outcome
In osteoarthritis patients, calcitonin pharmacodynamic parameters did not differ between baseline and day 14.
In plain wordsIn osteoarthritis patients, calcitonin pharmacodynamic parameters did not differ between baseline and day 14.
Peptide
Calcitonin-salmon
Outcome
No significant changePharmacodynamic parameters over time
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · oral · 14 daysAs given in this study (human).
Source sentences
Summary
No differences were observed between baseline and follow-up at day 14 in pharmacokinetic and pharmacodynamic parameters.
2 context sentences(design, population, supporting numbers)
Summary · context
The study was a phase-I, 2-week, placebo-controlled, double-blind, double-dummy, randomized, gender-stratified study including 73 subjects aged 57-75 years.
Summary · context
Treatment allocations were; 0.6 mg, 0.8 mg of oSCT, or placebo. Treatment was given twice daily for 14 days.
Report a problemFND-1974758106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 1NCT00486369

SMC021A - Absorption, Efficacy and Tolerance in Patients With Osteoarthritis. A Placebo-Controlled 14-Days Study

Nordic Bioscience A/SStart Jan 2007

Osteoarthritis

Trial page ClinicalTrials.govUpdated 14 Jun 2007

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.